This hypothesis posits that when a prostate tumor arises in a naturally low-testosterone environment, it may already be adapted to grow with minimal reliance on androgen stimulation. In such cases, administering androgen deprivation therapy (ADT)—the standard treatment aimed at starving the tumor of testosterone—could paradoxically backfire. Instead of suppressing the tumor, ADT may trigger an adaptive response, encouraging the cancer to further exploit alternative growth pathways it has already begun to utilize. This could potentially accelerate tumor aggressiveness, progression, and resistance, particularly by promoting neuroendocrine or castration-resistant phenotypes earlier in the disease course. Thus, in these patients, ADT might be not only ineffective but counterproductive. And my testosterone was below the minimum.